Scholarlink

<p>Within the last 5&#xa0;years, the FDA approved use of the Amplatzer Piccolo Occluder (Abbot Structural Heart, CA) for transcatheter patent ductus arteriosus (PDA) closure in premature infants. Other devices have been used off-label to successfully perform this procedure, including the Microvascular Plug, “MVP” (Medtronic, Minneapolis, MN). We report the largest single-center experience with PDA closure in premature infants using the MVP device. A retrospective review of transcatheter premature infant PDA closures at a single center was performed. Procedures performed using the MVP device were included; procedures using other devices were excluded. Descriptive statistics were performed using R version 4.4.0. From 4/2018 to 8/2022, a total of 74 cases were performed. The median gestational age was 24 (IQR 23–25) weeks and procedural weight was 1.17&#xa0;kg (0.97–1.40); (82% ≤ 1.5&#xa0;kg). The age at procedure was 44&#xa0;days (34–54). PDA minimum diameter (by angiogram) was 2.85 (2.4–3.4) mm. There were no procedural or 30-day mortalities. There was one major Adverse Event (AE) (aortic arch obstruction; 1.3%). There were two minor AEs (2.6%; small pericardial effusion requiring no intervention, <i>n</i> = 1; and device malposition with uneventful retrieval and replacement of additional device within the same catheterization, <i>n</i> = 1). The left pulmonary artery peak gradient at most recent follow-up was 5.8 (3.4–8.9) mmHg; the aortic peak gradient was 0.77 (0.4–1.7). There is a median follow-up time of 63&#xa0;days (32–310) post-procedure. The safety profile using the MVP is in line with or favorable compared to the contemporary literature of PDA closure in premature infants.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Largest Single-Center Experience Using the Micro Vascular Plug (MVP) for Transcatheter Closure of Premature Patent Ductus Arteriosus

  • 期刊论文

  • 发表日期：

    2025年3月27日

查看全文
  • Peter Guyon,
  • Dijana Popevski,
  • Thomas Forbes,
  • Brian Boe,
  • Kak-Chen Chan,
  • Larry Latson

摘要

Within the last 5 years, the FDA approved use of the Amplatzer Piccolo Occluder (Abbot Structural Heart, CA) for transcatheter patent ductus arteriosus (PDA) closure in premature infants. Other devices have been used off-label to successfully perform this procedure, including the Microvascular Plug, “MVP” (Medtronic, Minneapolis, MN). We report the largest single-center experience with PDA closure in premature infants using the MVP device. A retrospective review of transcatheter premature infant PDA closures at a single center was performed. Procedures performed using the MVP device were included; procedures using other devices were excluded. Descriptive statistics were performed using R version 4.4.0. From 4/2018 to 8/2022, a total of 74 cases were performed. The median gestational age was 24 (IQR 23–25) weeks and procedural weight was 1.17 kg (0.97–1.40); (82% ≤ 1.5 kg). The age at procedure was 44 days (34–54). PDA minimum diameter (by angiogram) was 2.85 (2.4–3.4) mm. There were no procedural or 30-day mortalities. There was one major Adverse Event (AE) (aortic arch obstruction; 1.3%). There were two minor AEs (2.6%; small pericardial effusion requiring no intervention, n = 1; and device malposition with uneventful retrieval and replacement of additional device within the same catheterization, n = 1). The left pulmonary artery peak gradient at most recent follow-up was 5.8 (3.4–8.9) mmHg; the aortic peak gradient was 0.77 (0.4–1.7). There is a median follow-up time of 63 days (32–310) post-procedure. The safety profile using the MVP is in line with or favorable compared to the contemporary literature of PDA closure in premature infants.